Table 3.
Sarcoma subtype | Circulating nucleic acid | Molecular target | Analysis method | Sample | Diagnostic value | Prognostic assessment | Response to therapy | Reference |
---|---|---|---|---|---|---|---|---|
OS | ctDNA | TP53,ATRX,DLG2,andMET mutations | tNGS | Plasma | √ | 64 | ||
Chrosome 8q | ddPCR+NGS | Plasma | √ | 59 | ||||
OS | ctRNA | miR-542-3p | RT-qPCR | Serum | √ | √ | 79 | |
miR-221 | RT-qPCR | Serum | √ | √ | 80 | |||
miR-191 | RT-qPCR | Serum | √ | √ | 81 | |||
miR-124 | RT-qPCR | Serum | √ | √ | 83 | |||
miR-421 | RT-qPCR | Serum | √ | √ | √ | 82 | ||
miR-25-3p | RT-qPCR | Serum | √ | √ | √ | 84 | ||
miR-21 | RT-qPCR | Serum | √ | √ | 85 | |||
miR-491 | RT-qPCR | Serum | √ | 87 | ||||
miR-101 | RT-qPCR | Serum | √ | 89 | ||||
miR-497 | RT-qPCR | Serum | √ | 90 | ||||
OS | ctRNA | miR-195 | RT-qPCR | Serum | √ | √ | 88 | |
miR-375 | RT-qPCR | Serum | √ | √ | 91 | |||
miR133b and miR-206 | RT-qPCR | Serum | √ | √ | √ | 92 | ||
miR199a-3p, miR-21 and miR-143 | RT-qPCR | Serum | √ | √ | 93 | |||
miR-215-5p andmiR-642a-5p | RT-qPCR | Serum | √ | 94 | ||||
miR-21, miR-221 and miR-106a | RT-qPCR | Serum | √ | 95 | ||||
miR-106a-5p, miR16-5p, miR-20a-5p, miR-425-5p, miR451a, miR-25-3P and miR139-5p | RT-qPCR | Serum | √ | √ | 96 | |||
OS | ctRNA | lncRNA TUG1 | RT-qPCR | Whole blood | √ | 111 | ||
LncRNA UCA1 | RT-qPCR | Plasma | √ | 112 | ||||
ES | ctDNA | STAG2 and TP53 | NGS | Plasma | √ | 59, 118 | ||
EWS/FLI and EWS/ERG fusion sequences |
dPCR | Plasma | √ | √ | 18, 59, 63 | |||
mtDNA | RT-qPCR | Serum | √ | √ | 126 | |||
ES | ctRNA | EWS/FLI1 and EWS/ERG transcripts | RT-qPCR | Plasma | √ | √ | 119-122 | |
miR-125b | RT-qPCR | Serum | √ | 127 | ||||
CS | ctDNA | mutant IDH1/IDH2 | dPCR | Plasma | √ | √ | 133 | |
LPS | ctDNA | TERT C228T break point t(12:16) | qPCR | Plasma | √ | 60 | ||
TP53 | NGS | Plasma | √ | 147 | ||||
ctRNA | miR-3613-3p | RT-qPCR | Whole blood | √ | 149 | |||
SS | ctDNA | SYT-SSX fusion sequence | Nested PCR | Peripheral blood | √ | 150-152 | ||
ctRNA | miR-92b-3p | RT-qPCR | Serum | √ | √ | √ | 155 | |
miR-99a-5p, miR-146b-5p, miR-148b-3p, miR-195-5p, miR-223-3p, miR-500b-3p and miR-505-3p | RT-qPCR | Serum | √ | √ | 56 | |||
RMS | ctDNA | PAX3-FOXO1 fusion | ddPCR | Plasma | √ | √ | 159, 160 | |
miR-1, miR-133a, miR-133b and miR-206 | RT-qPCR | Serum | √ | 162 | ||||
LMS | ctDNA | TP53, RB1 and PTEN | ULP-WGS | Plasma | √ | 166 | ||
ctDNA | TP53, PIK3CA and HRAS | tNGS | Plasma | √ | 50 | |||
ctRNA | miR-199b-5p, miR-320a, miR-199a-3p, miR-126, andmiR-22 | RT-qPCR | Plasma | √ | √ | 170 | ||
GIST | ctDNA | KIT or PDGFRA | L-PCR or dPCR | Plasma | √ | √ | √ | 174-180 |
Abbreviations: tNGS: targeted next generation sequencing; cNGS: custom next generation sequencing; L-NGS: ligation-next generation sequencing; ULP-WGS: ultra-low passage whole-genome sequencing; ddPCR: droplet-digital polymerase chain reaction; dPCR: digital polymerase chain reaction; RT-qPCR: real time quantitative polymerase chain reaction; L-PCR: ligation-polymerase chain reaction